MNPR

Monopar Therapeutics
$110.33
+$0.46 (+0.42%)Jul 27, 2026
4.5NeutralMoatMint rating

MoatMint rates Monopar Therapeutics (MNPR) 4.5 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 1.0 out of 10.

Key metrics

The numbers that frame MNPR today
Market cap
$739.11M
P/E (TTM)
-49.3
EV / FCF
-68.6
ROIC
-32.2%
Div yield
0%
Debt / equity
0.0
52wk Low
$29.18
52wk High
$116.64

MNPR stock rating

How MNPR scores on quality, value, growth, momentum and financial health
4.5out of 10
Neutral overallFair business, full priceTop 55% of ~5,000 US stocks
QualityPoor1.0/10
GrowthNeutral4.4/10
MomentumGreat9.0/10
ValueFair3.5/10
Financial HealthGreat8.0/10

Growth

Revenue and earnings trend for MNPR
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about MNPR
Is Monopar Therapeutics a good buy?
Hold. Monopar Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks weak. That could put pressure on the long-term business case. We think Monopar Therapeutics is selling at a high price.
What is the market capitalization of MNPR?
Monopar Therapeutics's market capitalization is $739.11M.
What is the P/E ratio for MNPR stock?
Monopar Therapeutics's current P/E ratio is -49.3.
What is the 52-week high for MNPR stock?
The 52-week high for Monopar Therapeutics is $116.64. The current close of $110.33 is 5.4% below that high.
What is the 52-week low for MNPR stock?
The 52-week low for Monopar Therapeutics is $29.18. The current close of $110.33 is 278.1% above that low.
Does MNPR stock pay dividends?
Monopar Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for MNPR?
Monopar Therapeutics's Debt / Equity ratio is 0.